The FDA recently approved a biosimilar (trade name, Amjevita) to Humira (adalimumab). A biosimilar is a biological product that is highly similar to the originator drug, and has no clinical differences in terms of safety and effectiveness.
Dr. Edward Loftus , M.D., talks about the potential of this drug to offer patients with chronic inflammatory diseases such as Crohn's and ulcerative colitis an additional treatment option, and explains the issues surrounding it.
For more information about IBD, visit mayoclinic.org/IBD.
Dr. Loftus is a gastroenterologist at Mayo Clinic.